Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16886300 | 0.91 | ACE (0.44) | POLBACE | |
| SCHEMBL13661861 | 0.90 | BTK (0.38) | HTTHSD17B10ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL18768899 | 0.88 | POLB (0.37) | POLBHTTTHRATHRBHSD17B10 | |
| SCHEMBL18751737 | 0.88 | POLB (0.37) | POLBHTTTHRATHRBHSD17B10 | |
| SCHEMBL29515941 | 0.88 | ALDH1A1 (0.33) | HSD17B10ALDH1A1HBB | |
| SCHEMBL6140852 | 0.88 | — | — | |
| SCHEMBL16704552 | 0.88 | POLB (0.37) | POLBHTTTHRATHRBHSD17B10 | |
| SCHEMBL18751690 | 0.88 | ALDH1A1 (0.33) | HSD17B10ALDH1A1HBB | |
| SCHEMBL25658422 | 0.87 | THRA (0.32) | THRATHRB | |
| SCHEMBL14379962 | 0.85 | CHRM2 (0.32) | POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058775-B2 | Insulin dimer-incretin conjugates | MERCK SHARP & DOHME CORP. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10953076-B2 | Insulin receptor partial agonists and GLP-1 analogues | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10800827-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190142906-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10183981-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME LLC | 2019-01-22 | — | — | US | disclosed |
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800827-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | POLB 3593/4885HTT 2068/4885THRA 37/4885 |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | IAPP, GLP1R, GIPR | POLB 4796/4885HTT 181/4885THRA 982/4885 |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | POLB 3593/4885HTT 2068/4885THRA 37/4885 |
| US-11058775-B2 | Insulin dimer-incretin conjugates | IAPP, GLP1R, GIPR | POLB 4796/4885HTT 181/4885THRA 982/4885 |
| US-20190142906-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | GLP1R, GIPR, IAPP | POLB 4220/4885HTT 691/4885THRA 86/4885 |
| US-10953076-B2 | Insulin receptor partial agonists and GLP-1 analogues | GLP1R, GIPR, IAPP | POLB 4220/4885HTT 691/4885THRA 86/4885 |
| US-10183981-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | POLB 3593/4885HTT 2068/4885THRA 37/4885 |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | POLB 3593/4885HTT 2068/4885THRA 37/4885 |
| US-10017556-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | POLB 3593/4885HTT 2068/4885THRA 37/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | POLB 3593/4885HTT 2068/4885THRA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.